[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642739":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":25,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":88,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Multiple Myeloma Participants","EXPERIMENTAL","Adults with multiple myeloma who are scheduled to receive CAR T-cell therapy. Participants will undergo baseline dynamic 18F-FDG PET\u002FCT and X-ray dual-energy CT imaging before CAR T-cell therapy. Participants will also undergo follow-up dynamic 18F-FDG PET\u002FCT and X-ray dual-energy CT imaging after CAR T-cell therapy.",[13,14],"Diagnostic Test: PET-enabled dual-energy CT imaging","Diagnostic Test: X-ray dual-energy CT imaging",{"label":16,"type":10,"description":17,"interventionNames":18},"Healthy Participants","Healthy adult participants without a history of cardiovascular, inflammatory, infectious, or metabolic diseases expected to affect bone marrow. Participants will undergo one dynamic 18F-FDG PET\u002FCT and X-ray dual-energy CT imaging visit.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","PET-enabled dual-energy CT imaging","18F-FDG will be administered intravenously for dynamic PET\u002FCT imaging.",[16,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"X-ray dual-energy CT imaging","Participants will undergo X-ray dual-energy CT imaging. Measurements from X-ray dual-energy CT will be used as the reference method for comparison with PET-enabled dual-energy CT measurements.",[16,9],[31],{"name":32,"affiliation":5,"role":33},"Guobao Wang, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Clinical Research Coordinator Team","CONTACT","916-731-9004","research-radiology-som@health.ucdavis.edu",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"UC Davis EXPLORER Molecular Imaging Center","Sacramento","California","95816","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-121.4944,38.58157,{"lat":52,"lon":51},[55,56],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[60],{"name":61,"class":62},"National Institute for Biomedical Imaging and Bioengineering (NIBIB)","NIH","100642739","pet-enabled-dual-energy-ct-in-multiple-myeloma-100642739",false,"NCT07646873","PET-Enabled Dual-Energy CT in Multiple Myeloma","PET-enabled Dual-energy CT for Oncological Applications","Inclusion Criteria:\n\nFor all research participants:\n\n* Adults (age ≥ 18 years old)\n* Ability to understand and willingness to sign an informed consent form\n* Ability to adhere to the study visit schedule and other protocol requirements.\n* Willing and able to fast for at least 6 hours before and for the duration of the scan\n* No strenuous exercise for 24 hours prior to being scanned\n* Willing to lie on the scanner bed for up to 60 minutes\n\nFor healthy volunteers only:\n\n• Free of history of cardiovascular, inflammatory, infections or metabolic diseases that would result in changes in bone marrow.\n\nFor cancer patients only:\n\n* Patients with multiple myeloma who are planned to receive CAR T-cell therapy with any FDA-approved product, including Idecel and Ciltacel. Patients with prior chemo-immunotherapy are permitted.\n* Able to undergo bone marrow aspirate\u002Fbiopsy procedure\n\nExclusion Criteria:\n\n* Self-reported history of dysphoria or anxiety in closed spaces\n* Body weight \\>240 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available)\n* Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only. That is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient.\n* Prisoners\n* Any condition that would prevent the understanding or rendering of informed consent.\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.",true,"ALL","18 Years",{"count":74,"type":75},45,"ESTIMATED","INTERVENTIONAL",[78],"NA","This pilot study will evaluate a new imaging method called PET-enabled dual-energy CT for measuring bone and soft-tissue composition in bone marrow. The study will enroll adults with multiple myeloma who are scheduled to receive CAR T-cell therapy and healthy adult participants.\n\nAll participants will undergo research imaging with dynamic 18F-FDG PET\u002FCT and X-ray dual-energy CT. Participants with multiple myeloma will have imaging before CAR T-cell therapy and again after therapy. Healthy participants will have one imaging visit.\n\nThe main goal is to compare bone and soft-tissue fraction measurements from PET-enabled dual-energy CT with measurements from standard X-ray dual-energy CT. The study will also explore whether corrected PET measurements are associated with bone marrow measurable residual disease, treatment response, and CAR T-cell therapy toxicities in participants with multiple myeloma.\n\nThis study is not expected to provide direct medical benefit to participants. The information learned may help improve future PET\u002FCT imaging methods for cancer evaluation.",[81],"Multiple Myeloma (MM)",[83,84,85,86,87],"PET-enabled dual-energy CT","Dual-energy CT","PET\u002FCT","18F-FDG","Multiple Myeloma","NOT_YET_RECRUITING","2026-06-09",{"date":91,"type":92},"2026-06-15","ACTUAL",{"date":94,"type":75},"2026-07",{"date":96,"type":75},"2030-11",{"name":5,"class":6},1]